Logo of National Eczema Association mobile menu icon
Icon link to National Eczema's Instagram feed. Icon link to National Eczema's YouTube channel. Icon link to National Eczema's Facebook page. Icon link to National Eczema's Twitter feed. Icon link to National Eczema's inspire.com page. Search Icon to search the site

Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.

Clinical Trial Details for A Multicenter Randomized Control Trial in Children With Moderate to Severe Atopic Dermatitis to Assess the Benefit of a Nurse-led One-to-one Education Program in Addition to Standard Care Compared to Standard Care Alone on the Long Term Control of Disease Severity at 6 Months


Nantes University Hospital
NCT ID: NCT02634905
Last Updated: March 11, 2019

The Study at a Glance

  • Status: Recruiting
  • Phase: N/A
  • Gender: All
  • Age: 3 Months - 18 Years
  • Condition: Dermatitis, Atopic
  • Study Type: Interventional
  • Intervention:
  • Lead Sponsor: Nantes University Hospital
  • Location: Not Provided

Official Title

A Multicenter Randomized Control Trial in Children With Moderate to Severe Atopic Dermatitis to Assess the Benefit of a Nurse-led One-to-one Education Program in Addition to Standard Care Compared to Standard Care Alone on the Long Term Control of Disease Severity at 6 Months

Purpose

- Atopic dermatitis is a chronic relapsing disease, which is highly prevalent in children (15%). Therapeutic patient education (TPE) has been recognized as a key priority topic for future AD research. The strongest evidence in favour of TPE efficacy in AD comes from a large study assessing repeated multi-disciplinary group education sessions in a hospital setting. However, this type of intervention is both resource and time consuming and is not adapted to typical French practice. However, in some french dermatology centers, simple "first level" nurse-led TPE interventions are offered in addition to physicians consultations. Unfortunately, the content of these interventions seems to vary greatly depending on the caregiver and the center and the benefits of these practices have not yet been assessed. Therefore, nurse-led TPE is not considered as current care in France for AD patients. - Thus, there is a need to rigorously assess the benefits of additional, well-structured, simple nurse-led individual TPE interventions for children with AD and their families compared to standard care alone. This study will be the first large, adequately powered, multicenter RCT trial assessing this type of intervention in children with AD.

Eligibility

Ages Eligible for Study

3 Months to 18 Years

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Criteria

Inclusion Criteria:

– Patient with AD, defined according to the criteria of the United Kingdom Working Party
: AD should be diagnosed when a child has an itchy skin condition plus three or more
of the following: Protocol EDU DA RC15_0035 Version n°4 du 15/09/16 Page 28 sur 44
CONFIDENTIAL Visible flexural dermatitis involving the skin creases, such as the bends
of the elbows or behind the knees (or visible dermatitis on the cheeks and/or extensor
areas in children aged under 10 years) Personal history of flexural dermatitis (or
dermatitis on the cheeks and/or extensor areas in children under 10 years) Personal
history of dry skin in the last 12 months Personal history of asthma or allergic
rhinitis (or history of atopic disease in a firstdegree relative of children aged
under 4 years)

– Onset of signs and symptoms under the age of 2 years (this criterion should not be
used in children aged less than 4 years). Patient aged at least 3 months and less than
18 years.

– SCORAD 20 (moderate to severe AD)

– Patient who received treatment an anti-inflammatory topical treatment (topical
corticosteroid or topical tacrolimus)

– Informed consent of parents

– Agreement of the child when appropriate

– Patient affiliated to French social security system

Exclusion Criteria:

– Patient does not meet the criteria of AD

– SCORAD < 20 - Patient aged 18 years or more - Patient treated with oral corticosteroids currently or systemic immunosuppressant 2 months prior to the eligibility assessment - Patients with primary immunodeficiency diseases. - Consent not given - Patient not affiliated to French social security system - Patient with intercurrent disease, may be excluded if the investigator believes participation in the trial is not in the best interest of the patient - Personal decision of the child or their parents not to be included - Child and / or parents lack the mental capacity to give informed consent - Child / Parents do not have a sufficient command of the French language for understanding TPE program. - Patient or parent who has already received structured TPE for AD.

Additional Information, Locations & Contacts

Sponsors & Collaborators

Nantes University Hospital

Investigators

Study Director: Sebastien BARBAROT, Dr

CHU Nantes

Please refer to this study by its ClinicalTrials.gov identifier: NCT02634905

Location

Contacts

Chu Bordeaux

Bordeaux,

France

Chru Brest

Brest,

France

Groupe Hospitalier de L Institut Catholique de Lille

Lille,

France

Hospices Civils

Lyon,

France

AP-HM

Marseille,

France

Chu Montpellier

Montpellier,

France

Chru Nancy

Nancy,

France

Chu Nantes

Nantes,

France

CHU NICE

Nice,

France

Chu Rennes

Rennes,

France

Chu Toulouse

Toulouse,

France